Stifel initiates research coverage of Xlife Sciences

Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent Office

Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)

Xlife Sciences initiates a review of strategic options

Xlife Sciences with pleasing progress in the first half of 2022

Xlife Sciences: First Valuation Report confirms substancial potential of the project portfolio and assumes CHF 574 million in the most conservative scenario